Abstract
The aim of this study was to evaluate possible correlation between routes of administration of levodopa in patients diagnosed with Parkinson�s disease and the presence of digestive symptoms. We included in this study 31 patients diagnosed with Parkinson�s disease:14 patients were on oral levodopa and 17 patients were on intrajejunal administration of levodopa/carbidopa. Each patient was assessed using Non-motor Symptoms Questionnaire for Parkinson�s Disease regarding the dysfunction of gastrointestinal tract. The results of our study indicated that there is a different distribution of the digestive dysfunction between the two groups of patients. The study indicate that the constipation was more frequent in those patients with oral medication.
Highlights
The aim of this study was to evaluate possible correlation between routes of administration of levodopa in patients diagnosed with Parkinson’s disease and the presence of digestive symptoms
non-motor symptoms (NMS) include 10 domains ranging from dysfunction of gastrointestinal tract to miscellaneous, and – as reported by a European study, more than 90% of patients did not mention or discuss the NMS they are experiencing until the clinicians became aware of them [5].The presence of NMS in the clinical presentation of Parkinson’s disease (PD) patients has been accompanied by a trend towards a more patients-centered approach to the diagnosis and treatment of the disease [6]
31 patients diagnosed with advanced Parkinson’s disease established by Movement Disorder Society Clinical Diagnostic Criteria for Parkinson’s disease were included in this study [9]. They were divided in 2 groups: group A composed of 14 patients (10 men and 4 women, with a mean age 69.7) that were treated with oral levodopa and 17 patients (8 men and 9 women, with a mean age 65.3) treated with levodopa/carbidopa intrajejunal infusion
Summary
31 patients diagnosed with advanced Parkinson’s disease established by Movement Disorder Society Clinical Diagnostic Criteria for Parkinson’s disease were included in this study [9]. They were divided in 2 groups: group A composed of 14 patients (10 men and 4 women, with a mean age 69.7) that were treated with oral levodopa and 17 patients (8 men and 9 women, with a mean age 65.3) treated with levodopa/carbidopa intrajejunal infusion. The gastrointestinal domain includes dribbling of saliva, ageusia, dysphagia/choking, vomiting/nausea, constipation, unsatisfactory voiding of bowel and fecal incontinence This questionnaire must be completed by the patient, checking the no or yes box. For comparations we used one tailed student t-test and for correlation - Pearson R test, with the statistical significance established when p
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
